MYGN

MYRIAD GENETICS INC

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)

4.3d↑+19.1%

as of 2026-09-15

News Summary

Negative

Myriad Genetics missed Q2 2026 revenue consensus by ~8% ($190.7M vs. $206-208M) and slashed full-year guidance by ~$90M midpoint just three months after reiterating prior guidance, citing reimbursement pressure, collections issues, and weak prenatal performance. The company suspended adjusted EBITDA guidance, reported a $0.25 adjusted EPS loss, and faces a securities investigation over the timing of the guidance reversal, with analyst downgrades (including Piper Sandler's rare double-downgrade to $2 PT) reflecting concerns about profitability and business model sustainability.

Red flags

•Q2 revenue missed consensus by ~8% ($190.7M vs. ~$207M expected)
•Full-year 2026 guidance cut by ~$90M midpoint (~10% reduction) only 3 months after reaffirmation on May 5, 2026
•Adjusted EBITDA guidance suspended entirely (previously $37-49M range)
•Securities investigation by Levi & Korsinsky over guidance reversal timing and potential securities law violations
•Q2 YoY revenue decline of 11% with average revenue per test down 9% YoY
•Adjusted EPS loss of $0.25 for Q2
•Gross margin guidance reduced to 66-67% (from 68-69%)
•Rare double-downgrade by Piper Sandler with $2 price target citing weak results and business model concerns
•Multiple management/leadership transitions in 2025-2026 (CFO separation, accounting leadership change, recent Commercial EVP appointment)
•Prenatal testing volume underperformance and reimbursement friction in Hereditary Cancer Testing

Fund 13D/13G Filings (2)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

Fund	Form	∆ Shares	% of Class	Since Filing	Filed	Src
Glenview Capital	SC 13G/A	—	0.0%	+51.1% vs SPY +51.2% abs	2026-08-14	↗
Glenview Capital	SC 13G	NEW	5.3%	—	2026-01-13	↗

Tracked Funds Holding (1)

Fund	Manager	Shares Held	Position Value
Point72	Steve Cohen	239K	$1M

Quarter-end 13F positions for the tracked funds holding this stock.